


ABSTRACT

CRF ANTAGONISTIC QUINO- AND QUINAZOLINES

This invention concerns compounds of formula



including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R¹ is C₁₋₆alkyl, NR⁶R⁷, OR⁶ or SR⁷; R² is hydrogen, C₁₋₆alkyl, C₁₋₆alkyloxy or C₁₋₆alkylthio; R³ is Ar¹ or Het¹; R⁴ and R⁵ are each independently selected from hydrogen, halo, C₁₋₆alkyl, C₁₋₆alkyloxy, trifluoromethyl, cyano, nitro, amino, and mono- or di(C₁₋₆alkyl)amino; R⁶ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfoxy or C₁₋₆alkylthio; R⁷ is hydrogen, C₁₋₈alkyl, mono- or di(C₃₋₆cyclo-alkyl)methyl, C₃₋₆cycloalkyl, C₃₋₆alkenyl, hydroxyC₁₋₆alkyl, C₁₋₆alkylcarbonyloxy-C₁₋₆alkyl or C₁₋₆alkyloxyC₁₋₆alkyl; R⁶ is C₁₋₈alkyl, mono- or di(C₃₋₆cycloalkyl)-methyl, Ar²CH₂, C₁₋₆alkyloxyC₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₃₋₆alkenyl, thienylmethyl, furanylmethyl, C₁₋₆alkylthioC₁₋₆alkyl, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonylC₁₋₆alkyl; or R⁶ and R⁷ taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C₁₋₆alkyl or C₁₋₆alkyloxyC₁₋₆alkyl; and Ar¹ and Ar² are each optionally substituted phenyl; and Het¹ is optionally substituted pyridinyl; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).